Abstract

The prostate tumor microenvironment plays important roles in the metastasis and hormone-insensitive re-growth of tumor cells. Bone marrow-derived mesenchymal stem cells (BM-MSCs) are recruited into prostate tumors to facilitate tumor microenvironment formation. However, the specific intrinsic molecules mediating BM-MSCs’ migration to prostate tumors are unknown. BM-MSCs’ migration toward a conditioned medium (CM) of hormone-insensitive (PC3 and DU145) or hormone-sensitive (LNCaP) prostate tumor cells was investigated using a three-dimensional cell migration assay and a transwell migration assay. PC3 and DU145 expressed transforming growth factor-β (TGF-β), but LNCaP did not. Regardless of TGF-β expression, BM-MSCs migrated toward the CM of PC3, DU145, or LNCaP. The CM of PC3 or DU145 expressing TGF-β increased the phosphorylation of Smad2/3 in BM-MSCs. Inactivation of TGF-β signaling in BM-MSCs using TGF-β type 1 receptor (TGFBR1) inhibitors, SB505124, or SB431542 did not allow BM-MSCs to migrate toward the CM. The CM of PC3 or DU145 enhanced N-cadherin expression on BM-MSCs, but the LNCaP CM did not. SB505124, SB431542, and TGFBR1 knockdown prevented an increase in N-cadherin expression. N-cadherin knockdown inhibited the collective migration of BM-MSCs toward the PC3 CM. We identified N-cadherin as a mediator of BM-MSCs’ migration toward hormone-insensitive prostate tumor cells expressing TGF-β and introduced a novel strategy for controlling and re-engineering the prostate tumor microenvironment.

Highlights

  • Prostate tumors are the most frequent malignancy and the second leading cause of cancer-related death in men worldwide [1]

  • Bone marrow-derived mesenchymal stem cells (BM-MSCs) migrated toward the conditioned medium of PC3 (PC3 CM), DU145 (DU145 CM), or LNCaP (LNCaP CM) (Figure 1A,B)

  • We demonstrated that N-cadherin mediates the migration of BM-MSCs toward conditions mimicking hormone-insensitive prostate tumor cells expressing transforming growth factor-β (TGF-β)

Read more

Summary

Introduction

Prostate tumors are the most frequent malignancy and the second leading cause of cancer-related death in men worldwide [1]. Androgen deprivation therapy is the primary treatment for metastatic prostate tumors through medical or surgical castration. Patients frequently develop castration resistance, making prostate tumor cells resistant to androgen deprivation therapy despite the retention or amplification of the androgen receptor in prostate tumor cells [1,2,3]. The tumor microenvironment of prostate tumors consists of various non-tumor cells, including immune cells, endothelial cells, and fibroblasts [1,4]. Mesenchymal stem cells of bone marrow are rare and multipotent stem cells that can be differentiated into different cell types of skeletal lineage, such as osteoblasts [7].

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call